Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Noble Corporation plc (NE) vs Sanofi SA (SNY) Price & Performance

Noble Corporation plcTrade

Price performance (Past 24H)

Key statistics

Noble Corporation plc vs Sanofi SA — how do they compare? Noble Corporation plc trades at $43.75 (market cap $7.10B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 14.7× Noble Corporation plc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.

NESNY
Market Cap
$7.10B$104.30B
Sector
TechnologyHealth
52-Week High
$54.37$52.34
52-Week Low
$26.61$41.33
Enterprise Value
$8.53B$124.19B
Dividend Yield
4.5%5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Noble Corporation plc

No Aura AI signal available yet.

Sanofi SA

SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.

The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Noble Corporation plc

Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.

Read more on NE

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY